{"nctId":"NCT01820572","briefTitle":"A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based","startDateStruct":{"date":"2013-03-27","type":"ACTUAL"},"conditions":["Kidney Transplantation"],"count":446,"armGroups":[{"label":"Belatacept","type":"EXPERIMENTAL","interventionNames":["Drug: Belatacept"]},{"label":"CNI","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tacrolimus","Drug: Cyclosporine"]}],"interventions":[{"name":"Belatacept","otherNames":["BMS 224818","Nulojix®"]},{"name":"Tacrolimus","otherNames":[]},{"name":"Cyclosporine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Men and women, ages 18-75 inclusive\n* Adult recipients of a renal allograft from a living donor or a deceased donor between 6-60 months prior to enrollment\n* Receiving a stable (≥1 month) regimen of Calcineurin inhibitor (CNI) \\[Cyclosporine A (CsA) or Tacrolimus (TAC)\\] with Mycophenolate mofetil (MMF) or Enteric Coated Mycophenolate Sodium (EC-MPS)/Mycophenolic acid (MPA), and corticosteroids\n* Stable renal function for 12 weeks prior to enrollment without new onset proteinuria\n* Calculated glomerular filtration rate (cGFR) ≥30 and ≤75 mL/min/1.73 m2 \\[Modification of Diet in Renal Disease study (MDRD) 4-formula\\]\n\nExclusion Criteria:\n\n* Recipients with Epstein-Barr virus (EBV) serostatus negative or unknown\n* History of acute rejection (AR) within 3 months prior to enrollment\n* History of antibody mediated rejection\n* Positive T-cell lymphocytotoxic cross match\n* Proteinuria \\>1 g/day or \\>0.5 g/day if diabetic","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Survive With a Functional Graft at 24 Months","description":"Percentage of participants who survive with a functional graft at 24 months post-randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Survive With a Functional Graft at 12 Months","description":"Percentage of participants who survive with a functional graft at 12 months post-randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Biopsy Proven Acute Rejection (BPAR)","description":"The number of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization\n\nincludes participants with at least one cellular and/or humoral BPAR event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Varying Severity of BPAR","description":"Number of participants in each severity of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Percent Change","description":"Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Percent Change","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"-0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Adjusted Change","description":"Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Adjusted Change","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"-0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Calculated Glomerular Filtration Rate (cGFR)","description":"Mean cGFR by study visit, as calculated by the 4-variable MDRD equation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.8","spread":null},{"groupId":"OG001","value":"49.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":null},{"groupId":"OG001","value":"50.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":null},{"groupId":"OG001","value":"50.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"50.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":null},{"groupId":"OG001","value":"50.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null},{"groupId":"OG001","value":"50.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5","spread":null},{"groupId":"OG001","value":"51.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":null},{"groupId":"OG001","value":"51.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Slope Analysis of cGFR","description":"Slopes of cGFR as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.241","spread":null},{"groupId":"OG001","value":"0.004","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.281","spread":null},{"groupId":"OG001","value":"-0.159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.685","spread":null},{"groupId":"OG001","value":"-0.112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.658","spread":null},{"groupId":"OG001","value":"-0.277","spread":null}]}]}]},{"type":"SECONDARY","title":"Slope Analysis of 1/Serum Creatinine","description":"Slopes of 1/serum creatinine as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.034","spread":null},{"groupId":"OG001","value":"-0.003","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.033","spread":null},{"groupId":"OG001","value":"-0.021","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00868","spread":null},{"groupId":"OG001","value":"-0.00203","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00814","spread":null},{"groupId":"OG001","value":"-0.00425","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With > 5% and >10% Improvement Over Baseline cGFR","description":"Percentage of participants with \\> 5% and \\>10% improvement over baseline cGFR, at 12 and 24 months post-randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":null},{"groupId":"OG001","value":"28.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.3","spread":null},{"groupId":"OG001","value":"29.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":null},{"groupId":"OG001","value":"22.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Urine Protein/ Creatinine Ratio (UPCR)","description":"Urine protein/ creatinine ratio (UPCR) at baseline, 3, 6, 12 and 24 months post randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.80","spread":null},{"groupId":"OG001","value":"18.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.87","spread":null},{"groupId":"OG001","value":"20.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.42","spread":null},{"groupId":"OG001","value":"20.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.11","spread":null},{"groupId":"OG001","value":"21.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.81","spread":null},{"groupId":"OG001","value":"24.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Systolic and Diastolic Blood Pressure","description":"Mean change in systolic and diastolic blood pressure from baseline to 12 and 24 months post randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"-0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Antihypertensive Medications Used to Control Hypertension","description":"The total number of antihypertensive medications used to control hypertension","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Donor Specific Antibodies (DSA)","description":"Number of participants with donor specific antibodies (DSA) at Baseline/Day 1, and Months 12 and 24 post-randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Number of Symptom Occurrence and Symptom Distress","description":"The frequency of symptom occurrence and symptom distress as measured with the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59R (MTSOSD-59R) at baseline, Week 6, and Months 3, 6, and 12 post-randomization.\n\nHigher scores in the MTSOSD-59R indicate a greater symptom and symptom distress burden than lower scores.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.8","spread":"20.06"},{"groupId":"OG001","value":"90.7","spread":"21.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.7","spread":"27.07"},{"groupId":"OG001","value":"34.8","spread":"28.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.0","spread":"16.52"},{"groupId":"OG001","value":"88.6","spread":"21.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":"21.41"},{"groupId":"OG001","value":"32.4","spread":"29.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":"16.74"},{"groupId":"OG001","value":"89.9","spread":"23.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":"23.08"},{"groupId":"OG001","value":"35.2","spread":"32.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.5","spread":"17.50"},{"groupId":"OG001","value":"91.8","spread":"23.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":"22.18"},{"groupId":"OG001","value":"36.3","spread":"31.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":"20.08"},{"groupId":"OG001","value":"91.0","spread":"22.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":"25.32"},{"groupId":"OG001","value":"34.4","spread":"30.82"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an Adverse Event of Special Interest","description":"Number of participants with an adverse event of special interests. Adverse events of special interest include:\n\nSerious Infections, Post-Transplant Lymphoproliferative Disorder (PTLD), Progressive multifocal leukoencephalopathy (PML), Malignancies (other than PTLD) including non-melanoma skin carcinomas, Tuberculosis Infections, CNS infections, Viral Infections and Infusion related reactions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Marked Laboratory Abnormalities","description":"Number of participants with Marked Laboratory Abnormalities","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Vital Signs: Heart Rate","description":"The mean change from baseline in measured heart rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null},{"groupId":"OG001","value":"-0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":107,"n":221},"commonTop":["Diarrhoea","Nasopharyngitis","Urinary tract infection","Oedema peripheral","Cough"]}}}